Translating Data to Patient Care: A Case Study in HFrEFPremiere Date: Tuesday, October 5, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, October 5, 2022
Note: Credit Is No Longer Available
|Javed Butler, MD, MPH, MBA (Moderator)
Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
Professor of Physiology
University of Mississippi Medical Center
|Alanna Morris, MD, MSc, FHFSA, FACC, FAHA
Associate Professor of Medicine, Division of Cardiology
Emory University School of Medicine
Director of Heart Failure Research
Emory University Clinical Cardiovascular Research Institute
Updated practice guidelines and recently approved novel therapies provide improved strategies to optimize care for patients with heart failure (HF), particularly heart failure with reduced ejection fraction (HFrEF). Among these advances are tools and biomarkers for risk stratification, the use of sodium glucose-cotransporter-2 (SGLT2) inhibitors for appropriate patients with or without type 2 diabetes, and the role of a new soluble guanylate cyclase (sGC) inhibitor to reduce the risk of cardiovascular death and HF hospitalizations in worsening disease.
The key to improving patient care is regular clinical implementation of the new recommendations. This CMEOCast episode features two experts in HF assessing a patient who presents with worsening HFrEF, discussing additional workups that would be helpful, optimizing his current medication regimen, and sequencing newer therapies. Faculty will also discuss strategies on how to utilize shared decision-making and avoid racial and ethnic bias to ensure all patients receive appropriate, guideline-directed medical therapy.
At the end of this CE activity, participants should be able to:
- Individualize your treatment plan for patients with HFrEF to reduce readmissions, improve quality of life, and optimize long-term outcomes.
- Recognize the prevalence of HFrEF in communities of color and address barriers to optimal care.
Supported by an educational grant from Merck Sharp & Dohme Corp.
Cardiologists, PCPs, PAs, NPs, Nurses, Pharamcists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Butler reports that he is on the speakers bureau for AstraZeneca; Boehringer Ingelheim (BI)-Lilly Alliance; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. He is a consultant for Abbott; Adrenomed; Amgen Inc.; Applied Therapeutics; Array BioPharma Inc.; AstraZeneca; Bayer; Boehringer Ingelheim; CVRx; G3 Pharmaceuticals; Impulse Dynamics; Innolife Pharma, Inc.; Janssen Pharmaceuticals, Inc; LivaNova; Luitpold Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Relypsa, Inc.; Sequanna Medical; and Vifor Pharma, Inc.
Dr. Morris reports that she receives research support from the Association of Black Cardiologists; National Institutes of Health/National Heart Lung, and Blood Institute; and the Robert W. Woodruff Foundation, Inc. She also reports Institutional Research Support (paid to Emory University): Alnylam Pharmaceuticals; Amgen Inc.; Boston Scientific Corporation; Eidos Therapeutics; Ionis; Merck & Co., Inc.; MyoKardia, Inc.; National Heart, Lung, and Blood Institute (NHLBI); and Pfizer Inc. She is a shareholder with direct purchase with Gilead Sciences, Inc.
Warren Beckman (planning committee) has no disclosures to report.
Michael Franks, APRN, AGACNP-BC, FNP-BC
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).